XINT — Xintela AB Share News
0.000.00%
Last trade - 00:00- SEK200.68m
- SEK190.89m
- SEK2.28m
Brief: Xintela Raises Around SEK 28 Mln In Directed New Share Issue
Brief: Xintela Q1 Pretax Loss Widens To SEK 9.0 Million
Brief: Xintela's GMP Facility Approved For Manufacturing Of Cell Therapy Products
Brief: Xintela Reports Results From Preclinical Ards Study And Grant Of SEK 2.3 Mln
Brief: Xintela Gets Tissue Establishment License
Brief: Xintela Gets Patent Grant In Europe For XSTEM Stem Cell Product
Brief: Xintela Publishes Results From Glioblastoma Antibody Study
Brief: Xintela Q4 Loss Before Tax Widens To SEK 25.3 Mln
Corrected: (OFFICIAL)-BRIEF-Xintela Carries Out Issue Of Shares (Jan 12)
Brief: Xintela Carries Out Issue Of Shares
Brief: Xintela Gets Notice Of Allowance From USPTO For Treatment Of Brain Tumors
Brief: Xintela Submits Manufacturing License Application
Brief: Xintela: Arbitral Award Rendered In Favour Of Co In Dispute With Former Underwriters
Brief: Xintela Q3 Loss Before Tax Widens To SEK 8.3 Mln
Brief: Xintela Receives 'Intention To Grant' Decision From European Patent Office
Brief: Xintela's Stem Cells Show Promising Results In Preclinical ARDS Study
Brief: Xintela Q2 Pretax Loss Narrows To SEK 9.1 Million
Brief: Xintela Gets Notice Of Allowance From USPTO For Quality Assurance Of Chondrocyte-Based Products
Brief: Xintela Rights Issue Gets Oversubscribed